Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)

ClinicalTrials.gov ID: NCT02082522

Public ClinicalTrials.gov record NCT02082522. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 5, 2026, 1:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Multicenter, Open-label, Randomized, Controlled Phase III Clinical Study of the Efficacy and Safety of Photodynamic Therapy Using Porfimer Sodium for Injection as Treatment for Unresectable Advanced Perihilar Cholangiocarcinoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Photodynamic therapy (PDT) is a combination of a drug, porfimer sodium (Photofrin), which is activated by a light from a laser that emits no heat. This technique works to allow the medical doctor to specifically target and destroy abnormal or cancer cells while limiting damage to surrounding healthy tissue. The activation of the drug is done by lighting the abnormal areas using a fiber optic device (very fine fiber like a fishing line that permits light transmission) inserted into a flexible tube with a light called cholangioscope for the bile duct. The light will activate the porfimer sodium concentrated in the abnormal tissue, leading to its destruction. This research study will evaluate the efficacy and safety of PDT with porfimer sodium administered with Standard Medical Care (SMC) compared to SMC alone on the overall survival time of patients with non-operable advanced cholangiocarcinoma, a rare cancer of the bile ducts. It will involve 200 patients across North America and Europe. Other countries may participate if needed. Participation will last at least 18 months.

Study identification

NCT ID
NCT02082522
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Concordia Laboratories Inc.
Industry
Enrollment
28 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 11, 2014
Primary completion
Jan 11, 2017
Completion
Jan 11, 2017
Last update posted
Aug 27, 2019

2014 – 2017

United States locations

U.S. sites
18
U.S. states
11
U.S. cities
17
Facility City State ZIP Site status
Western Regional Medical Center, Inc. Goodyear Arizona 85338
Mayo Clinic Cancer Center Scottsdale Arizona 85259-5499
University of Southern California Keck School of Medicine Los Angeles California 90033-1026
UC Davis Medical Center Sacramento California 95817
University of Colorado Denver Aurora Colorado 80045
Oschner Medical Center Kenner Louisiana 70065
Henry Ford Health System Detroit Michigan 48202
SUNY Downstate Medical Center Brooklyn New York 11203
Roswell Park Cancer Institute Buffalo New York 14263
Weill Cornell Medical College New York New York 10021
Columbia University Medical Center New York New York 10032
Duke University Medical Center Durham North Carolina 27710
Southwestern Regional Medical Center, Inc. Tulsa Oklahoma 74133
Thomas Jefferson University Philadelphia Pennsylvania 19107
Allegheny Center for Digestive Health - AHN ASRI Pittsburgh Pennsylvania 15212
Methodist Dallas Medical Center Dallas Texas 75208
Virginia Mason Medical Center Seattle Washington 98101
Providence Sacred Heart Medical Center and Children's Hospital Spokane Washington 99204

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 13 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02082522, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 27, 2019 · Synced Sep 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02082522 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →